Sofinnova Ventures has raised $500 million for its latest biotechnology pool amid a resurgence in venture capital fundraising. Sofinnova surpassed its $425 million goal to reach the fund’s hard cap after seeing several companies go public or be acquired recently. They include ZS Pharma Inc.ZSPH -1.28%, which went public in June, and Labrys Biologics Inc., which has just been acquired by Teva Pharmaceutical Industries Ltd.
Image: http://blogs.wsj.com
